Top Markets
Coin of the day
Enochian Biosciences, Inc. Enochian Biosciences, Inc.

Enochian Biosciences, Inc.

ENOB
株式のランク #19952
Enochian Biosciences, Inc. is a pre-clinical biotechnology firm dedicated to... Enochian Biosciences, Inc. is a pre-clinical biotechnology firm dedicated to the research and advancement of novel pharmaceutical and biological agents. Its primary focus lies in developing treatments for a range of human diseases, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza, coronavirus infections, and various cancers. The company's leading investigational products encompass ENOB-HV-01, an autologous therapy aimed at achieving an HIV cure; ENOB-HV-11, a preventative HIV vaccine candidate; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, which targets the HBV polymerase. Beyond these primary programs, Enochian Biosciences' developmental pipeline also features ENOB-DC-11, an off-the-shelf dendritic cell vaccine designed for multiple solid tumors, and ENOB-DC-21, a non-specific vaccine intended for direct intratumoral injection. The company collaborates strategically with prominent research organizations such as The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Founded in 2017, Enochian Biosciences, Inc. operates from its headquarters in Los Angeles, California.
株価
$2.60
最終同期: 2023-08-29
時価総額
$145.54M
変化(1日)
9.24%
変化(1年)
0.00%
US
取引 Enochian Biosciences, Inc. (ENOB)

カテゴリー

Enochian Biosciences, Inc.(ENOB)の収益
Aug 2026 時点の収益 TTM: 0
Enochian Biosciences, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Enochian Biosciences, Inc. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$12.62B -
US
$6.02B -
NL
$2.23B -
US
$15.74B -
AU
- -
CH